21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
Launched by LEO PHARMA · Sep 7, 2011
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This is the standard patch test over 21 days of exposure of the test product,its vehicle and a positive as well as a negative control.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy volunteers
- • male ore female subjects
- • aged 18 - 65 years
- • ability to understand and fulfill the study requirements
- Exclusion Criteria:
- • affected skin in designated test area
- • pregnancy or lactation
- • not willing to comply with study requirements
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fargo, North Dakota, United States
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials